Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ) just unveiled an update.
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its trastuzumab biosimilar, Dazublys®, intended for treating HER2-positive breast cancers. This endorsement marks an important step for Aurobindo Pharma in strengthening its biosimilars portfolio, with expectations for European Commission approval by July, furthering its commitment to launching at least ten biosimilars by 2030 to enhance cancer care and address unmet patient needs.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Limited, through its subsidiary CuraTeQ Biologics, is a global biopharmaceutical company based in Hyderabad, India, focusing on developing biosimilars for cancer and autoimmune diseases. The company aims to provide high-quality, cost-effective therapies with a pipeline of fourteen biosimilars targeting immunology and oncology segments.
YTD Price Performance: -6.94%
Average Trading Volume: 34,176
Current Market Cap: 730.4B INR
For an in-depth examination of AUROPHARMA stock, go to TipRanks’ Stock Analysis page.